We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Can4.0

Canakinumab Research

Mostly mechanism / observationalLimited safety

6 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Canakinumab studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality meta-analyses and randomised trials published 2009–2025 with a typical study size of 237 participants.

Based on 6 studies · 1 meta-analysis · 5 RCTs · 10,333 total participants

Confidence

High

By outcome

Cardiovascular (CANTOS)
Mostly mechanism / observational4 studies
Inflammation & inflammaging
Mostly mechanism / observational3 studies
Cancer & periodic fever syndromes
Mostly mechanism / observational3 studies
Aging & healthspan (hypothesis)
Too few graded studies2 studies
Safety profile
Too few graded studies1 study

Active research area

2 studies in the last 5 years · Latest meta-analysis: 2025

200920172025

1RCTn=10,061 · very large study2017

Canakinumab at 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering.

Ridker, Everett, Thuren, MacFadyen, Chang, Ballantyne · The New England journal of medicine (2017)

CANTOS: randomized, double-blind, placebo-controlled trial in ~10,000 post-MI patients with elevated hsCRP
The 150 mg dose significantly reduced recurrent cardiovascular events — with no change in lipids
First hard-outcome proof that lowering inflammation itself, independent of cholesterol, improves cardiovascular outcomes

View source

2RCTn=237 · medium study2024

Adding canakinumab to docetaxel did not provide additional benefit for patients with advanced NSCLC who had progressed after chemotherapy and immunotherapy.

Paz-Ares, Goto, Wan-Teck Lim, Halmos, Chul Cho, Cobo · Lung cancer (Amsterdam, Netherlands) (2024)

CANOPY-2: phase 3 randomized, double-blind trial in advanced non-small-cell lung cancer
The trial did NOT meet its primary endpoint of overall survival (HR 1.06; no benefit)
The dedicated anticancer program failed to confirm the CANTOS lung-cancer signal

View source

3Meta-Analysis2025

Anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway reduced myocardial infarction and revascularization, with no benefit in mortality and increased infection risk.

Pan, Fan, Jiang, Zhang · Inflammation research (2025)

Systematic review and meta-analysis of 32 RCTs (37,056 patients) of anti-inflammatory therapies targeting the NLRP3/IL-1β/IL-6/CRP axis in coronary disease
The pathway reduced myocardial infarction and coronary revascularization but showed NO benefit in MACE, stroke, or cardiovascular/all-cause mortality
Found increased risks of infection, GI effects, and injection-site reactions — quantifying the trade-off

View source

4RCT2017

Hypothesis-generating data suggest anti-inflammatory therapy with canakinumab could reduce incident lung cancer and lung cancer mortality.

Ridker, MacFadyen, Thuren, Everett, Libby, Glynn · Lancet (2017)

Exploratory analysis of the CANTOS cohort — incident and fatal lung cancer as pre-specified secondary endpoints
Canakinumab was associated with dose-dependent reductions in incident lung cancer and lung cancer mortality (300 mg HR 0.33)
Generated major excitement for IL-1β blockade as an anticancer strategy

View source

5RCTn=35 · small study2009

Treatment with subcutaneous canakinumab once every 8 weeks induced and maintained remission in patients with cryopyrin-associated periodic syndrome.

Lachmann, Kone-Paut, Kuemmerle-Deschner, Leslie, Hachulla, Quartier · The New England journal of medicine (2009)

Registration RCT: three-part, randomized-withdrawal trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS)
97% had a complete response; disease flares occurred in 81% on placebo vs none on canakinumab during the withdrawal phase, with normalized CRP/SAA
The pivotal trial establishing the approved IL-1β-driven autoinflammatory indication

View source

6RCT2020

In a secondary analysis of CANTOS, IL-1β inhibition with canakinumab did not lower blood pressure or prevent incident hypertension.

Rothman, MacFadyen, Thuren, Webb, Harrison, Guzik · Hypertension (2020)

Pre-specified secondary analysis of the CANTOS cohort (10,061 post-MI patients with elevated hsCRP)
Canakinumab did not reduce blood pressure or prevent incident hypertension despite lowering inflammation
Shows the cardiovascular benefit is not mediated by blood-pressure lowering

View source

View in Research Library

Canakinumab Research

Mostly mechanism / observational

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.

Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Use of canakinumab in the cryopyrin-associated periodic syndrome.

Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.